Advertisement

Neurological Sciences

, Volume 39, Issue 9, pp 1625–1627 | Cite as

Neurobehçet, multiple sclerosis or overlap syndrome? A case report

  • Vittorio Mantero
  • Andrea Rigamonti
  • Anna Fiumani
  • Luisa De Toni Franceschini
  • Ugo Pozzetti
  • Roberto Balgera
  • Andrea Salmaggi
Letter to the Editor
  • 105 Downloads

Dear Editor,

According to the “McDonald criteria”, multiple sclerosis (MS) diagnosis requires the demonstration of dissemination in time (DIT) and in space (DIS) and no better explanation [1].

We report the case of a 25-year-old woman came to our attention complaining of sudden decrease of vision in both eyes and orbital pain increased by eye movements. Few years before, she had been diagnosed with Behçet’s disease (BD) on the basis of recurrent bilateral uveitis, oral aphthosis, positive pathergy test and positive HLAB51 and treated with methotrexate, infliximab, and prednisone, all suspended for personal decision from 5 years. At the age of 18, after 3 years of therapy with infliximab and 8 years after the diagnosis of BD, she reported a right sensory hemisyndrome and a brain MRI (without gadolinium for allergy) showed T2-weighted hyperintense lesions in the corpus callosum, bilateral centrum semiovale, and corona radiata.

On admission, visual acuity was 1/20 in the right and motus...

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest.

References

  1. 1.
    Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17:162–173CrossRefPubMedGoogle Scholar
  2. 2.
    Akman-Demir G, Mutlu M, Kiyat-Atamer A, Shugaiv E, Kurtuncu M, Tugal-Tutkun I, Tuzun E, Eraksoy M, Bahar S (2015) Behçet’s disease patients with multiple sclerosis-like features: discriminative value of Barkhof criteria. Clin Exp Rheumatol 33:S80–S84PubMedGoogle Scholar
  3. 3.
    Çoban O, Bahar S, Akman-Demir G et al (1999) Masked assessment of MRI findings: is it possible to differentiate neuro-Behçet’s disease from other central nervous system diseases? Neuroradiology 41:255–260CrossRefPubMedGoogle Scholar
  4. 4.
    Saruhan-Direskeneli G, Yentür SP, Mutlu M, Shugaiv E, Yesilot N, Kürtüncü M, Akman-Demir G (2013) Intrathecal oligoclonal IgG bands are infrequently found in neuro-Behçet’s disease. Clin Exp Rheumatol 31:25–27PubMedGoogle Scholar
  5. 5.
    Motomura S, Tabira T, Kuroiwa Y (1980) A clinical comparative study of multiple sclerosis and neuro-Behçet’s syndrome. J Neurol Neurosurg Psychiatry 43(3):210–213CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Newman NJ, Lessell S, Winterkorn JM (1991) Optic chiasmal neuritis. Neurology 41:1203–1210CrossRefPubMedGoogle Scholar
  7. 7.
    Kidd D (2011) The optic chiasm. Handb Clin Neurol 102:185–203CrossRefPubMedGoogle Scholar
  8. 8.
    Aoyagi R, Sakai T, Kono Y et al (2013) A case of Behçet’s disease with development of MS-like lesions in the CNS and spinal cord. Clin Exp Rheumatol 31:154PubMedGoogle Scholar
  9. 9.
    Antonazzo IC, Raschi E, Vignatelli L, Baldin E, Riise T, D’Alessandro R, de Ponti F, Poluzzi E (2017) Occurrence of multiple sclerosis after drug exposure: insights from evidence mapping. Drug Saf 40:823–834CrossRefPubMedGoogle Scholar
  10. 10.
    Gill C, Rouse S, Jacobson RD (2017) Neurological complications of therapeutic monoclonal antibodies: trends from oncology to rheumatology. Curr Neurol Neurosci Rep 17:75CrossRefPubMedGoogle Scholar
  11. 11.
    Kemanetzoglou E, Andreadou E (2017) CNS demyelination with TNF-α blockers. Curr Neurol Neurosci Rep 17:36CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Massacesi L, Tramacere I, Amoroso S, Battaglia MA, Benedetti MD, Filippini G, la Mantia L, Repice A, Solari A, Tedeschi G, Milanese C (2014) Azathioprine versus beta interferons for relapsing-remitting multiple sclerosis: a multicentre randomized non-inferiority trial. PLoS One 9:e113371CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Casetta I, Iuliano G, Filippini G (2007) Azathioprine for multiple sclerosis. Cochrane Database Syst Rev 17:CD003982Google Scholar
  14. 14.
    Messori A, Fadda V, Maratea D, Trippoli S (2014) Indirect meta-analytical comparison of azathioprine and of beta interferon effectiveness in all forms of multiple sclerosis pooled together. J Neurol Sci 347(15):408–410CrossRefPubMedGoogle Scholar
  15. 15.
    Ticha V, Kalincik T, Havrdova E (2012) Interferon-β or azathioprine as add-on therapies in patients with active multiple sclerosis. Neurol Res 34:923–930CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia S.r.l., part of Springer Nature 2018

Authors and Affiliations

  1. 1.Neurological DepartmentA. Manzoni HospitalLeccoItaly
  2. 2.Department of Internal MedicineA. Manzoni HospitalLeccoItaly

Personalised recommendations